BC Cancer Agency

Derm-Biome Pharmaceuticals’ topical therapy shows positive results in preclinical skin cancer trial: drug prevents the development of precancerous skin conditions and treats existing skin cancers with no observable side effects. 

Retrieved on: 
Mercredi, avril 17, 2024
University, Radiation, BC Cancer Agency, Mouse, Cell, Carcinoma, Skin, Aks, UVB, Topical medication, University of British Columbia, IND, Patient, BC Cancer Research Centre, Neoplasm, Toxicity, Medication, Pharmaceutical industry

VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world.

Key Points: 
  • VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world.
  • Treating AKs before the cells become cancerous and spread to other parts of the body is crucial.
  • For those patients with multiple AKs, common treatment options are chemotherapy creams and photodynamic therapy.
  • There is a real need for safer and more targeted topical therapies.”
    Derm-Biome expects to start topical formulation development this summer, with IND-enabling studies slated to begin in Q4.

Telix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.

Retrieved on: 
Jeudi, avril 11, 2024
Health, Transport, Logistics, Supply Chain Management, Health Technology, Pharmaceutical, Biotechnology, USD, Isotope, BC Cancer Agency, Actinium-225, PET, History, Cyclotron, Patient, GHS, Acquisition, Lawson Health Research Institute, TRIUMF

ARTMS Inc. (ARTMS) is pleased to announce that the acquisition by Telix Pharmaceuticals Limited (Telix) has been completed.

Key Points: 
  • ARTMS Inc. (ARTMS) is pleased to announce that the acquisition by Telix Pharmaceuticals Limited (Telix) has been completed.
  • This acquisition further enhances the vertical integration of Telix’s supply chain and manufacturing by providing a greater level of supply chain and regulatory control over the production of key isotopes.
  • The history of ARTMS is rooted in a Canadian government funded project focused on solid target production of 99mTc.
  • Solomon Partners Securities LLC acted as financial advisor and Norton Rose Fulbright Canada LLP acted as legal advisor to ARTMS during the negotiations and due diligence process related to the acquisition by Telix.

Acquisition of ARTMS, TRIUMF medical isotope spinoff, demonstrates value and impact of Canada's major research facilities

Retrieved on: 
Jeudi, avril 11, 2024
NISP, Isotope, BC Cancer Agency, Cancer, Commercialization, Research, University, ITAP, Acquisition, Private sector, Lawson Health Research Institute, TRIUMF, NRU, Pharmaceutical industry

As the largest-ever acquisition of a TRIUMF spin-off company, the deal stands as a striking symbol of the role of major science facilities in driving innovation and technological breakthroughs for the benefit of Canadians.

Key Points: 
  • As the largest-ever acquisition of a TRIUMF spin-off company, the deal stands as a striking symbol of the role of major science facilities in driving innovation and technological breakthroughs for the benefit of Canadians.
  • "We turned a major global challenge into an opportunity, and today what we do is fortifying isotope supply chains and empowering research on new, life-saving medical isotopes."
  • "Canada needs major infrastructure and national communities of experts and innovators like those that exist at TRIUMF to support and launch companies like ARTMS.
  • ARTMS' story is a powerful example of what we can accomplish when we invest in fundamental science and work together."

Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
Lundi, décembre 18, 2023
House (season 5), Risk, PSMA, NDA, Cancer, HR, PNT, Death, RLT, CTCAE, SPLASH, Patient, Safety, BC Cancer Agency, LNTH, Pharmaceutical industry

BEDFORD, Mass., and INDIANAPOLIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- December 18, 2023 – Lantheus Holdings, Inc. (Lantheus) (NASDAQ: LNTH) and POINT Biopharma Global Inc. (POINT) (NASDAQ: PNT) today announced statistically significant topline results from the pivotal Phase 3 SPLASH study evaluating the efficacy and safety of 177Lu-PNT2002, a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), in patients with metastatic castration-resistant prostate cancer (mCRPC) after progression on an androgen receptor pathway inhibitor (ARPI).

Key Points: 
  • BEDFORD, Mass., and INDIANAPOLIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- December 18, 2023 – Lantheus Holdings, Inc. (Lantheus) (NASDAQ: LNTH) and POINT Biopharma Global Inc. (POINT) (NASDAQ: PNT) today announced statistically significant topline results from the pivotal Phase 3 SPLASH study evaluating the efficacy and safety of 177Lu-PNT2002, a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), in patients with metastatic castration-resistant prostate cancer (mCRPC) after progression on an androgen receptor pathway inhibitor (ARPI).
  • “There is an urgent unmet need for targeted treatment options for mCRPC patients, particularly for those whose cancer has progressed on androgen receptor pathway inhibitors,” said Dr. Kim Chi, SPLASH Principal Investigator, Medical Oncologist, BC Cancer.
  • At the time of the analysis, interim overall survival (OS) results were immature (46% of protocol-specified target OS events reached), the HR was 1.11.
  • The companies expect additional, follow-up data in 2024 prior to the potential submission of a New Drug Application (NDA).

Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
Lundi, décembre 18, 2023
House (season 5), Risk, PSMA, NDA, Cancer, HR, PNT, Death, RLT, CTCAE, SPLASH, Patient, Safety, BC Cancer Agency, LNTH, Pharmaceutical industry

and INDIANAPOLIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus) (NASDAQ: LNTH) and POINT Biopharma Global Inc. (POINT) (NASDAQ: PNT) today announced statistically significant topline results from the pivotal phase 3 SPLASH study evaluating the efficacy and safety of 177Lu-PNT2002, a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), in patients with metastatic castration-resistant prostate cancer (mCRPC) after progression on an androgen receptor pathway inhibitor (ARPI).

Key Points: 
  • and INDIANAPOLIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus) (NASDAQ: LNTH) and POINT Biopharma Global Inc. (POINT) (NASDAQ: PNT) today announced statistically significant topline results from the pivotal phase 3 SPLASH study evaluating the efficacy and safety of 177Lu-PNT2002, a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), in patients with metastatic castration-resistant prostate cancer (mCRPC) after progression on an androgen receptor pathway inhibitor (ARPI).
  • “There is an urgent unmet need for targeted treatment options for mCRPC patients, particularly for those whose cancer has progressed on androgen receptor pathway inhibitors,” said Dr. Kim Chi, SPLASH Principal Investigator, Medical Oncologist, BC Cancer.
  • At the time of the analysis, interim overall survival (OS) results were immature (46% of protocol-specified target OS events reached), the HR was 1.11.
  • The companies expect additional, follow-up data in 2024 prior to the potential submission of a New Drug Application (NDA).

U.S. FDA Approves AKEEGA™ (Niraparib and Abiraterone Acetate), the First-And-Only Dual Action Tablet for the Treatment of Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
Vendredi, août 11, 2023
DSM-IV codes, Janssen Pharmaceuticals, Neoplasm, AE, Prostate cancer, Abiraterone acetate, CI, Drug, Constipation, BC Cancer Agency, Janssen, Prognosis, Mutation, AAP, RPF, CHES, ZERO, Science, Hypertension, Prednisone, Death, TCC, Patient, Hazard, TSP, Medicine, Cancer, HR, Genetic testing, Nausea, IA2, Johnson & Johnson, BRCA, FDA, PARP, Education, Disease, Safety, Fatigue, Pharmaceutical industry, Medical imaging, HORSHAM

HORSHAM, Pa., Aug. 11, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food & Drug Administration (FDA) has approved AKEEGA™ (niraparib and abiraterone acetate), the first-and-only dual action tablet combining a PARP inhibitor with abiraterone acetate, given with prednisone, for the treatment of adult patients with deleterious or suspected deleterious BRCA-positive mCRPC, as detected by an FDA-approved test.1

Key Points: 
  • *, Medical Oncologist at BC Cancer – Vancouver and principal investigator of the Phase 3 MAGNITUDE study.
  • "All individuals diagnosed with prostate cancer should consider genetic testing, especially those from racial and ethnic minority groups who tend to have worse cancer outcomes.
  • This is imperative to close the racial and ethnic disparities in prostate cancer health outcomes."
  • "This milestone, which marks the approval of Janssen's third prostate cancer treatment, highlights the importance of advancing precision medicine approaches and genetic testing for the treatment of patients with BRCA-positive mCRPC."

Patient Experience Journal Releases The Newest Volume: Volume 10, Issue 1

Retrieved on: 
Lundi, mai 1, 2023
Aston, Pediatric emergency medicine, Cleveland Clinic, University of Alabama, University, Aston University, BC Cancer Agency, University of Ottawa, University of Pennsylvania, Research, Montana State University, Safety (gridiron football position), Thought, University of Exeter, Sandwell and West Birmingham Hospitals NHS Trust, Sunnybrook Health Sciences Centre, Nursing, Book, Island Health

NASHVILLE, Tenn., May 1, 2023 /PRNewswire-PRWeb/ -- The Beryl Institute announces the publication of Volume 10, Issue 1 of Patient Experience Journal (PXJ), an international, open access, peer-reviewed journal focused on research and proven practices related to understanding and improving the patient experience. Read in over 220 countries and territories, PXJ articles have been downloaded over 1,100,000 times and reflect the journal's commitment to disseminating rigorous knowledge and expanding the global conversation on evidence and innovation in patient and human experience.

Key Points: 
  • It has become a place for conversation.
  • It has served as a conduit for expanding excellence in practice," said Jason Wolf, Founding Editor of PXJ and President & CEO of The Beryl Institute.
  • It is a shared sense of purpose and of possibility.
  • And we are forever grateful to our authors, reviewers and readers for being true champions for transforming the human experience."

New Council of Expert Advisors to support Canada's life sciences ecosystem

Retrieved on: 
Jeudi, mars 9, 2023
Community health, Human Genome Sciences, Infection, IWK Health Centre, Medical genetics, Epidemiology, Government of Canada, Therapy, Ecosystem, Public, CEA, Dalhousie University Faculty of Medicine, Growth, Council, Pandemic, BC Cancer Agency, The Honourable, Government, Investment, University, Pediatrics, COVID-19, UBC, Safety, Pharmaceutical industry, Science, Health

The CEA's first meeting focused on the previous steps taken under Canada's Biomanufacturing and Life Sciences Strategy and on its path forward.

Key Points: 
  • The CEA's first meeting focused on the previous steps taken under Canada's Biomanufacturing and Life Sciences Strategy and on its path forward.
  • The launch of the Council of Expert Advisors will be critical to the health and safety of Canadians by enhancing our preparedness for future pandemics and other health emergencies."
  • – The Honourable Jean-Yves Duclos, Minister of Health
    Canada's Biomanufacturing and Life Sciences Strategy presents a long–term vision to protect Canadians against future pandemics and other health emergencies and to grow an innovative, competitive domestic life sciences sector.
  • Budget 2021 provided a total of $2.2 billion over seven years toward growing a vibrant domestic life sciences sector and securing pandemic preparedness.

Janssen Presents Updated Data Demonstrating Improved Outcomes from the Use of Niraparib in Combination with Abiraterone Acetate Plus Prednisone as a First-Line Therapy in Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
Jeudi, février 16, 2023
Niraparib, Janssen Pharmaceuticals, PARP, BRCA, American Society of Clinical Oncology, Prostate cancer, BC Cancer Agency, Abstract, CI, ADP, Constipation, RN, Patient, Cancer, HR, Johnson & Johnson, TSP, Anemia, IA2, TCC, Causality, RPF, Hypertension, AAP, Gene, Abiraterone acetate, HRR, SAN, MSN, Society, Death, ASCO, Pharmaceutical industry, Medical imaging

SAN FRANCISCO, Feb. 16, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 3 MAGNITUDE study evaluating the investigational use of niraparib, a highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) with or without specific homologous recombination repair (HRR) gene alterations, including BRCA mutations. Results will be featured today in a Rapid Abstract Session (Abstract #170) at the American Society of Clinical Oncology's Genitourinary (ASCO GU) Cancers Symposium, taking place February 16-18.

Key Points: 
  • Patients without HRR gene alterations had no improvement in outcomes from the use of niraparib in combination with AAP.
  • "Taken together, these data continue to support the potential use of niraparib in combination with AAP in patients with mCRPC and BRCA mutations."
  • "We have confirmed the unmet need in patients with BRCA-mutated mCRPC and have shown that niraparib and abiraterone acetate plus prednisone overcomes the poor prognostic outcome in these patients.
  • "As the treatment landscape for prostate cancer continues to evolve, we are committed to evaluating innovative targeted therapies to help improve outcomes for patients with HRR-positive prostate cancer."

STEMCELL Technologies President and CEO Dr. Allen Eaves Appointed to the Order of Canada

Retrieved on: 
Jeudi, décembre 29, 2022
Research, Public Policy, Government, Stem Cells, Biotechnology, Other Health, White House, Federal Government, Health, General Health, Science, BC Cancer Agency, Mentorship, Friends, Research, Hope, University, Multimedia, Stemcell Technologies, Science, Acadia University, Biology, Development, Vancouver General Hospital, Research and development, Heart, Internal medicine, Dalhousie University, Oncology, Order, The Right Honourable, Senior, Hospital, Doctor of Philosophy, Management, Medical device

STEMCELL Technologies President and CEO Dr. Allen Eaves has been appointed to the Order of Canada -- one of the nation’s highest forms of recognition. (Photo: Business Wire)

Key Points: 
  • STEMCELL Technologies is proud to announce its President and CEO, Dr. Allen Eaves, has been appointed to the Order of Canada by Her Excellency the Right Honourable Mary Simon, the Governor General of Canada.
  • View the full release here: https://www.businesswire.com/news/home/20221229005015/en/
    STEMCELL Technologies President and CEO Dr. Allen Eaves has been appointed to the Order of Canada -- one of the nation’s highest forms of recognition.
  • (Photo: Business Wire)
    One of the nation’s highest forms of recognition, the Order of Canada recognizes people who make extraordinary contributions to Canadian society.
  • “Being appointed to the Order of Canada is an honour of a lifetime, and I am grateful for the countless colleagues, mentors, friends, and family members who supported me throughout my career,” Dr. Eaves said.